Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC decreased its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 31.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 281,863 shares of the company's stock after selling 131,774 shares during the period. TimesSquare Capital Management LLC owned approximately 0.22% of Vaxcyte worth $10,643,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. National Bank of Canada FI purchased a new stake in shares of Vaxcyte in the fourth quarter worth about $41,000. Parallel Advisors LLC boosted its holdings in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after purchasing an additional 1,071 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after purchasing an additional 293 shares during the last quarter. J.Safra Asset Management Corp boosted its holdings in Vaxcyte by 65.8% in the first quarter. J.Safra Asset Management Corp now owns 3,161 shares of the company's stock valued at $119,000 after purchasing an additional 1,254 shares during the last quarter. Finally, GF Fund Management CO. LTD. boosted its holdings in Vaxcyte by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 3,192 shares of the company's stock valued at $121,000 after purchasing an additional 575 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Vaxcyte Trading Down 3.1%

NASDAQ PCVX traded down $1.15 on Friday, hitting $36.22. 647,622 shares of the stock traded hands, compared to its average volume of 1,490,060. The stock has a 50-day moving average of $33.74 and a 200 day moving average of $54.16. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The company has a market capitalization of $4.67 billion, a P/E ratio of -9.09 and a beta of 1.19.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business posted ($0.85) earnings per share. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Cantor Fitzgerald assumed coverage on Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Bank of America reduced their price target on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. The Goldman Sachs Group reduced their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Vaxcyte currently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.